TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06499805

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Audiologist-based fitting
Description: Description hearing aids will be fitted by audiologists using established procedures.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Over-the-counter fitting
Description: In this group, over-the-counter hearing aids will be used by subjects. Subjects will take the full initiative and responsibility for learning and using hearing aids.
Study: NCT05650190

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Novel spectacle lens design
Description: Use of single vision, impact resistant spectacle lenses may reduce the rate of progression of juvenile myopia

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Spectacle lenses
Description: Single vision, impact resistant spectacle lenses
Study: NCT04771897

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BXQ-350 - Part 1 Dose Escalation: Safety and Tolerance
Description: BXQ-350 is a novel anti-neoplastic therapeutic agent configured from two components: Saposin C (SapC), an expressed (human) lysosomal protein, and the phospholipid dioleoylphosphatidyl-serine (DOPS), a phospholipid located on cell membranes (clinical formulation BXQ-350). During Part 1, BXQ-350 will be administered by intravenous (IV) infusion over twelve months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BXQ-350 - Part 2 BXQ-350 Tumor and Plasma Concentrations
Description: BXQ-350 is a novel anti-neoplastic therapeutic agent configured from two components: Saposin C (SapC), an expressed (human) lysosomal protein, and the phospholipid dioleoylphosphatidyl-serine (DOPS), a phospholipid located on cell membranes (clinical formulation BXQ-350). During Part 2, BXQ-350 will be administered by intravenous (IV) infusion over twelve months.
Study: NCT06651502

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: dental implant placement and immediate provisionalization
Description: dental implant placement and immediate temporization
Study: NCT05116085

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Administered intravenously
Study: NCT04671797

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early dinner
Description: Dinner at DLMO-3, sleep at DLMO+2

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early dinner
Description: Dinner at DLMO-3, sleep at DLMO+2

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early dinner
Description: Dinner at DLMO-3, sleep at DLMO+2

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Late Dinner
Description: Dinner at DLMO+1, sleep at DLMO+2

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Late Dinner
Description: Dinner at DLMO+1, sleep at DLMO+2

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Late Dinner
Description: Dinner at DLMO+1, sleep at DLMO+2

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Late Dinner + Late Sleep
Description: Dinner at DLMO+1, sleep at DLMO+6

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Late Dinner + Late Sleep
Description: Dinner at DLMO+1, sleep at DLMO+6

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Late Dinner + Late Sleep
Description: Dinner at DLMO+1, sleep at DLMO+6
Study: NCT04703166

Intervention type: DEVICE
Intervention: Samsung Galaxy Watch Active2
Description: The Samsung wearable device will collect data; photoplethysmography (PPG) waveforms, heart rate, heart rate variability, step counts, oxygen saturation levels, sleep pattern and quality.
Study: NCT06008353

Intervention type: OTHER
Intervention: Observational study
Description: This is an observational study; patients will not be exposed to clinical interventions different from those belonging to the standard of care.
Study: NCT05274659

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: KJ103
Description: Recombinant Immunoglobulin G Cleaving Enzyme

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: KJ103
Description: Recombinant Immunoglobulin G Cleaving Enzyme

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: KJ103
Description: Recombinant Immunoglobulin G Cleaving Enzyme

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: KJ103
Description: Recombinant Immunoglobulin G Cleaving Enzyme

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: KJ103
Description: Recombinant Immunoglobulin G Cleaving Enzyme

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT06417073

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Face-To-Face Task-orianted Training
Description: In this study, face-to-face task-oriented station training is provided by trained occupational therapists to elderly nursing home residents. Each session involves structured activities that simulate real-world challenges designed to improve cognitive and hand functions. These include exercises to enhance fine motor skills, hand strength, coordination, and cognitive tasks such as problem-solving and memory exercises.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tele-Rehabilitation Task-orianted Training
Description: This intervention utilizes video-conferencing technology to deliver task-oriented training to elderly nursing home residents, focusing on cognitive and hand function improvements.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home-based Task-orianted Training
Description: Home-Based Task-Oriented Training Intervention Description:~This home-based intervention involves a series of task-oriented activities specifically designed to improve cognitive and hand functions for elderly residents in nursing homes. Participants carry out prescribed activities independently, based on detailed guides provided by occupational therapists. The activities are tailored to stimulate cognitive processes and enhance fine motor skills, including tasks like sorting, assembling, and manipulative exercises that replicate daily challenges. Each participant follows a structured program of daily 45-minute sessions for two weeks, with periodic remote check-ins by therapists to assess progress and adjust the difficulty of tasks as needed. This format allows participants to engage in rehabilitation at their own pace, within the comfort of their own living spaces, fostering greater autonomy and adherence to the intervention.
Study: NCT06148233

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: [18F]CSF-23
Description: Intravenous injection of 1.8 MBq \[0.05MCi\]/kg of \[18F\]CSF-23 in a single dose.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: [18F]CSF-23
Description: Intravenous injection of 1.8 MBq \[0.05MCi\]/kg of \[18F\]CSF-23 in a single dose.
Study: NCT04875819

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neisseria meningitidis oligosaccharide conjugate vaccine and recombinant protein-based vaccine
Description: One dose (0.5 ml) of conjugate vaccine against meningococcal serogroups ACWY (Menveo®) and one dose of a recombinant protein-based vaccine against meningococcal serogroup B (Bexsero®) at day 0 followed by another dose (0.5 ml) of each vaccine at day 60.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 13 valent pneumococcal conjugate vaccine and 23 valent pneumococcal polysaccharide vaccine
Description: One dose (0.5 ml) of pneumococcal conjugate vaccine (Prevenar13®) at day 0 and one dose (0.5 ml) of pneumococcal polysaccharide vaccine (Pneumovax23®) at day 60.
Study: NCT05579314

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: XW014
Description: Oral tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: XW014
Description: Oral tablets
Study: NCT06180382

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: Administration of adalimumab with optimisation either 80 mg every 14 days by subcutaneous injection, or the same dose of 40 mg every 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab
Description: Strategy B: administration of vedolizumab 300mg by infusion at baseline, 14 days, 42 days and 60 days, followed by a dose of 108mg every fortnight by subcutaneous injection.
Study: NCT06585020

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arikayce
Description: Treatment regimens containing three molecules, rifampicin, ethambutol, and clarithromycin with ARIKAYCE® during the 6 first months of treatment. After having confirmed the presence of all inclusion criteria and the absence of all exclusion criteria, and after having obtained the patient's free and informed consent, the patient will be included and randomized to one of the treatment regimens.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard treatment
Description: treatment regimens containing three molecules, rifampicin, ethambutol, and clarithromycin during the 6 first months of treatment. After having confirmed the presence of all inclusion criteria and the absence of all exclusion criteria, and after having obtained the patient's free and informed consent, the patient will be included and randomized to one of the treatment regimens.
Study: NCT06104865

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tinnitus Sound Therapy using (Resound Tinnitus relief) mobile application
Description: Patient exposure to relieving sound(wind, rain, ocean waves, etc) of his own choice from the mobile phone application and using this effect with time to accommodate the brain to neglect the negative effects of tinnitus.
Study: NCT05114668

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EVT801
Description: Stage 1: Patients will be dosed orally with EVT801 capsules at the dose and schedule to which they are assigned.~Stage 2: Patients will be dosed orally with EVT801 capsules at the MTD / RP2D identified in Stage 1 of the study.
Study: NCT05579314

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Matched oral placebo tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched oral placebo tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: XW014
Description: Oral capsules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: XW014
Description: Oral capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched oral placebo capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched oral placebo capsules
Study: NCT05946395

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hearing aid
Description: Fitting a hearing aid

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hearing aid
Description: Fitting a hearing aid
Study: NCT06136806

Intervention type: DIAGNOSTIC_TEST
Intervention: Ferumoxytol Enhanced Magnetic Resonance Angiography（ FE-MRA）；Coronary/Renal /Lower artery Arteriography
Description: When the patient is suspected with multisite artery disease, FE-MRA and angiography will be performed according to the patient's clinical manifestation. For example, when the patient is suspected with coronary artery disease, coronary FE-MRA and angiography will be performed; when the patient is suspected with renal artery stenosis, renal artery FE-MRA and angiography will be performed; and when the patient is suspected with the lower extremity artery occlusion, the lower extremity artery FE-MRA and angiography will be performed.

Intervention type: DIAGNOSTIC_TEST
Intervention: Ferumoxytol Enhanced Magnetic Resonance Venography（ FE-MRV）, Computed Tomography Pulmonary Angiography, Ultrasound for Lower Extremity Deep Vein.
Description: When the patient is suspected with venous thromboembolism, the lower extremity vein FE-MRV, pulmonary FE-MRA and ultrasound for lower extremity deep vein as well as computed tomography pulmonary angiography will be taken to ensure whether the patient with thrombus or not.
Study: NCT05147987

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hands free wearable breast pump
Description: Use of a supplementary breast pump which can be discreetly worn and is hands free
Study: NCT05946395

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Speech therapy session
Description: As speech therapy is part of standard care, the objective of the study will be to compare the impact of synchronous or delayed audioprosthetic and speech therapy care on the impact of deafness in elderly patients.
Study: NCT06197880

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Anterior teeth retraction
Description: En masse retraction of the upper and lower anterior segments using maximum anchorage
Study: NCT04958187

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ANG-3777
Description: Arm assigned to this intervention will receive 2 mg/kg, IV
Study: NCT01714089

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RNS60 125 ml

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RNS60 250 ml

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Interferon beta 1a
Study: NCT05946395

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Speech therapy session
Description: As speech therapy is part of standard care, the objective of the study will be to compare the impact of synchronous or delayed audioprosthetic and speech therapy care on the impact of deafness in elderly patients.
Study: NCT05903131

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telemedicine behavioral weight intervention
Description: Weekly telephone calls during the first month, biweekly during the next 5 months, and then monthly for the last 7 months (12 months total). Each telephone session will be 30 minutes long.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progestin
Description: Released via the levonorgestrel-releasing IUD.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced usual care
Description: 1-3 page handouts

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levonorgestrel-releasing IUD.
Description: Standard of care

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levonorgestrel-releasing IUD.
Description: Standard of care
Study: NCT05029856

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SII B.1.351
Description: Intramuscular (deltoid) injections of 3 μg SII B.1.351 and 50 μg Matrix-M1 Adjuvant,~1 or 2 doses:1 on Day 0 and ± 1 on Day 21.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SII B.1.351
Description: Intramuscular (deltoid) injections of 3 μg SII B.1.351 and 50 μg Matrix-M1 Adjuvant,~1 or 2 doses:1 on Day 0 and ± 1 on Day 21.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SII B.1.351
Description: Intramuscular (deltoid) injections of 5 μg SII B.1.351 and 50 μg Matrix-M1 Adjuvant,~1 or 2 doses:1 on Day 0 and ± 1 on Day 21.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SII B.1.351
Description: Intramuscular (deltoid) injections of 5 μg SII B.1.351 and 50 μg Matrix-M1 Adjuvant,~1 or 2 doses:1 on Day 0 and ± 1 on Day 21.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SII Bivalent
Description: Intramuscular (deltoid) injections of 6 μg SII Bivalent and 50 μg Matrix-M1 Adjuvant, 2 doses: 1 on Day 0 and 1 on Day 21.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SII Bivalent
Description: Intramuscular (deltoid) injections of 10 μg SII Bivalent and 50 μg Matrix-M1 Adjuvant, 2 doses: 1 on Day 0 and 1 on Day 21.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SII B.1.617.2
Description: Intramuscular (deltoid) injections of 5 μg SII B.1.617.2 and 50 μg Matrix-M1 Adjuvant,~1 or 2 doses:1 on Day 0 and ± 1 on Day 21.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SII B.1.617.2
Description: Intramuscular (deltoid) injections of 5 μg SII B.1.617.2 and 50 μg Matrix-M1 Adjuvant,~1 or 2 doses:1 on Day 0 and ± 1 on Day 21.
Study: NCT06089187

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Endotracheal intubation using an endotracheal tube with cuff inflated with air
Description: After endotracheal intubation, the endotracheal tube cuff is inflated with air

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endotracheal intubation using an endotracheal tube with cuff inflated with saline
Description: After endotracheal intubation, the endotracheal tube cuff is inflated with saline
Study: NCT06195241

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DaxibotulinumtoxinA
Description: Patients with Benign Essential Blepharospasm (BEB) or Hemifacial spasms (HFS) will be treated with DaxibotulinumtoxinA-Lanm (Daxxify) using a 2:1 conversion rate of Daxxify to Botox.
Study: NCT06640933

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB091
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB091
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB091
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB091
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB091
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB091
Description: Administered as specified in the treatment arm.
Study: NCT05866211

Intervention type: OTHER
Intervention: Previous exposure to SARS-CoV-2
Description: This is an observational study in which no intervention will be applied.

Intervention type: OTHER
Intervention: Previous exposure to SARS-CoV-2
Description: This is an observational study in which no intervention will be applied.
Study: NCT06191315

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab
Description: Pharmaceutical form: Injection solution Route of administration: Subcutaneous

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form: Injection solution Route of administration: Subcutaneous
Study: NCT06433219

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tuvusertib (M1774)
Description: Tuvusertib will be administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tuvusertib (M1774)
Description: Tuvusertib will be administered orally
Study: NCT05824221

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS
Description: Non invasive brain stimulation in Cocaine Use Disorder
Study: NCT06433219

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Niraparib will be administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lartesertib (M4076)
Description: Lartesertib will be administered orally
Study: NCT04951648

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Almonertinib
Description: Almonertinib 165 mg，orally once a day Treatment can continue until disease progression, unacceptable toxicity or other discontinuation criteria are met.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: chemotherapy
Description: Pemetrexed (500mg/m2) plus Carboplatin (AUC5)or Pemetrexed (500mg/m2) plus Cisplatin (75mg/m2) on Day 1 of 21day cycles (every 3 weeks) for 4\~6 cycles, followed by pemetrexed mainten-ance therapy every 3 weeks until disease progress-ssion, unacceptable toxicity or other discontinuation criteria are met.
Study: NCT05824221

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: rTMS
Description: Non invasive brain stimulation in Cocaine Use Disorder
Study: NCT04902482

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iCycle Mark 3
Description: The iCycle Mark 3 is a cycle ergometer, designed to be used by people with SCI while they are seated in their own wheelchairs. The purpose of iCycle is to stimulate the leg muscles in the correct phase for cycling while motivating the person with a Virtual Reality cycling event, perhaps a race, to try to use their muscles.
Study: NCT05395143

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zinc sulfate
Description: Zinc sulfate tablet 30mg once daily orally for 8 weeks along with Atorvastatin.
Study: NCT02832505

Intervention type: OTHER
Intervention: No intervention but only observational
Description: This study is a cross-sectional and observational MRI study with three cohorts of patients, and no interventions will be applied.

Intervention type: OTHER
Intervention: No intervention but only observational
Description: This study is a cross-sectional and observational MRI study with three cohorts of patients, and no interventions will be applied.

Intervention type: OTHER
Intervention: No intervention but only observational
Description: This study is a cross-sectional and observational MRI study with three cohorts of patients, and no interventions will be applied.
Study: NCT05395143

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet 30mg once daily orally for 8 weeks along with Atorvastatin.
Study: NCT06366165

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: seemingly irrelevant funny videos and memes in teaching
Description: linking funny videos and memes to special care dentistry curriculum lectures
Study: NCT06065774

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: The Laterally Closed Tunnel Technique with SCTG
Description: Local anesthesia using 4% articane with 1:100.000 epinephrine was applied.•~Then specially designed tunneling instruments \[devmed\] were used through the sulcular incision to create a pouch.~A microsurgical blade was used at the inner surface of the pouch till sufficient tissue release was achieved.~Tissue forceps was used to approximate the mesial and distal margin of the gingiva at the pouch margin.~After harvesting the graft, it was placed at the prepared pouch after root surface biomodification using EDTA gel 24% for 2 minutes and copious rinsing with saline solution.~SCTG was pulled using single or mattress sutures and the graft was fixed mesial and distal at the inner part of the pouch using resorbable suture material \[Vicryl suture\], then the graft was sutured around the neck of the CEJ by sling suture 6/0 polypropylene.
Study: NCT06085638

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given by SC (under the skin) or IV (vein)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given by SC (under the skin) or IV (vein)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamibarotene
Description: Given by PO
Study: NCT05024045

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LOXO-338
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LOXO-338
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirtobrutinib
Description: Oral